Peter D Urrea

Learn More
PURPOSE The conversion rate of tegafur (a component of S-1) to fluorouracil (FU) differs in Asians and whites because of polymorphic differences in the CYP2A6 gene. S-1 with cisplatin is considered highly active in Japanese gastric cancer patients. Therefore, we initiated a phase I pharmacokinetic study of this combination in our gastric cancer patients. (More)
S-1 is a novel oral fluoropyrimidine that combines tegafur with CDHP and oxonic acid. To decrease the incidence of late onset, severe diarrhea observed in a previous study, a phase I study was conducted to determine the maximum tolerated dose (MTD) of S-1 utilizing a 14-day schedule, repeated every 21 days, in patients with chemotherapy–refractory upper(More)
4043 Background: S-1 (Tegafur, Oxonic acid, & CDHP), an active oral drug against AGC, combined with Cis resulted in a >70% response rate in Japan ( Br J Cancer 89:2207, 2003). METHODS A phase I study of S-1 & Cis with pharmacokinetics (PKs) in patients (Pts) with AGC was performed to determine the MTD in the 1st cycle. The starting dose of S-1 (Level 1)(More)
CONTEXT Pancreatic cancer is the third most common gastrointestinal malignancy in the United States. Due to difficulty in diagnosis, 40% of patients are stage IV by the time of diagnosis and median survival is only four to six months. Current therapy for advanced pancreatic cancer focuses largely on gemcitabine. However, a relatively new drug, S-1, is(More)
  • 1